Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system

Abstract

ABSTRACT Introduction Mucormycosis is a rare invasive fungal infection (IFI), which is characterized by prolonged antifungal therapy, high morbidity and mortality rates, as well as increased treatment costs. Areas covered Appropriate diagnosis of mucormycosis is a fundamental component of successful treatment; however, evidence about health economic expenses does not exist. Based on an international guideline approach for the diagnosis of mucormycosis, we calculated costs for imaging-based and laboratory procedures and susceptibility testing from the German statutory health insurance perspective. We therefore analyzed the diagnostic recommendations for patients at increased progression risk, i.e. neutropenia, previous solid organ transplantation, or hematopoietic stem cell transplantation. Expert opinion From the health economic point of view, our analysis underlines the relevance of appropriate guideline-based diagnosis of mucormycosis. The overall costs are relatively low (€499.40 per case) compared to other components in the management of mucormycosis, such as cost-intensive treatment with antifungal agents. Nevertheless, it is important to bear in mind that the level of diagnostic accuracy in line with the global guidelines by the European Confederation of Medical Mycology and the Mycoses Study Group Education and Research Consortium requires substantial resources, which may not be available in all countries or centers, especially in those with low income.